Companies › LYEL

LYELL IMMUNOPHARMA INC (LYEL)

Institutional ownership, SEC filings and insider activity

Sector: Healthcare & Pharma · SEC CIK 0001806952 · EDGAR filings · Updated 2026-07-27

LYELL IMMUNOPHARMA INC (LYEL) has reported institutional ownership of 51.4%, with 73 institutional managers holding positions valued at $237.2M per the latest 13F reporting period. SEC filings include an active notice of delisting or failure to satisfy a continued listing rule (8-K Item 3.01).

Filings this week (2)

• 2026-07-27 — Insider transaction reported (Form 4)
• 2026-07-27 — Insider transaction reported (Form 4)

Every filing links to the official SEC document. Real-time filing alerts for this company are available inside the app.

Latest updates

• 2026-07-21 — EFFECT filed
• 2026-07-20 — Insider transaction reported (Form 4)
• 2026-07-17 — Insider transaction reported (Form 4)
• 2026-07-13 — Shelf registration (S-3) filed

Institutional ownership overview

According to SEC 13F filings tracked by Sightfile, LYELL IMMUNOPHARMA INC has 73 institutional holders and institutional ownership of 51.4%.

Insider activity

Insiders reported 37 transactions (2 buys, 25 sells) across 14 reporting insiders, with a net reported value of $24.5M.

Data flags from SEC filings

Related companies

Immix Biopharma Inc (IMMX) · AGOMAB THERAPEUTICS NV (AGMB) · PROTARA THERAPEUTICS INC (TARA) · RXSIGHT INC (RXST) · STRATA CRITICAL MEDICAL INC (SRTA) · OVID THERAPEUTICS INC (OVID)